Recent Price Movement and Market Performance
On 04-Dec, Sequent Scientific’s shares closed at ₹207.65, down ₹5.05 or 2.37% from the previous session. This decline is part of a broader short-term downtrend, with the stock losing 8.28% over the past week, significantly underperforming the Sensex benchmark, which fell only 0.53% in the same period. Over the last month, the stock has declined 5.20%, whereas the Sensex gained 2.16%, highlighting a divergence from the broader market’s positive momentum.
The stock has been on a consecutive five-day losing streak, accumulating an 8.64% drop during this period. Intraday, the share price touched a low of ₹206.20, reflecting a 3.06% decline on the day. This short-term weakness contrasts with the stock’s longer-term performance, where it has delivered a 17.98% gain year-to-date and an impressive 119.50% return over three years, substantially outperforming the Sensex’s 35.62% gain over the same timeframe.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Technical Indicators and Investor Activity
From a technical perspective, the stock is trading above its 100-day and 200-day moving averages, signalling underlying medium- to long-term strength. However, it remains below its 5-day, 20-day, and 50-day moving averages, indicating short-term selling pressure. This technical setup suggests that while the stock retains a solid foundation, recent momentum has weakened.
Investor participation has also diminished, with delivery volume on 03-Dec falling by 14.05% compared to the five-day average, signalling reduced buying interest. Despite this, liquidity remains adequate, with the stock’s trading volume supporting a trade size of approximately ₹0.76 crore based on 2% of the five-day average traded value. This level of liquidity ensures that the stock remains accessible to active traders and institutional investors.
Strong Financial Performance Underpins Valuation
Fundamentally, Sequent Scientific has demonstrated robust growth. The company reported a remarkable 209.15% increase in net profit in its September quarter, marking the seventh consecutive quarter of positive results. Profit before tax excluding other income surged by 246.43% to ₹26.71 crore, while profit after tax rose 162.7% to ₹15.97 crore. These figures underscore the company’s operational efficiency and expanding profitability.
The company’s return on capital employed (ROCE) stands at a healthy 10.65% for the half-year, reflecting effective utilisation of capital. Additionally, the stock trades at a fair valuation, with an enterprise value to capital employed ratio of 4.6, which is lower than the average historical valuations of its peers. This discount suggests that the stock may be undervalued relative to comparable companies in the sector.
Over the past year, despite the stock’s modest 1.57% price appreciation, profits have grown by 128.2%, resulting in a price-to-earnings-to-growth (PEG) ratio of 1. This metric indicates that the stock’s price is aligned with its earnings growth, supporting the view that the current valuation is reasonable.
Holding Sequent Scien. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: Short-Term Weakness Amid Solid Fundamentals
In summary, Sequent Scientific’s recent share price decline is primarily driven by short-term market dynamics, including technical resistance and reduced investor participation. The stock’s underperformance relative to the Sensex and its sector over the past week and month reflects a phase of profit-taking or cautious sentiment among traders.
However, the company’s strong financial results, consistent profit growth, and fair valuation metrics provide a solid foundation for the stock’s medium- to long-term prospects. Investors may view the current weakness as a potential entry point, given the company’s demonstrated ability to deliver sustained earnings growth and its attractive valuation relative to peers.
Majority ownership by promoters further adds to the stability of the shareholding structure, which can be reassuring for investors seeking confidence in management’s commitment.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
